Motivational and Neurocognitive Deficits Are Central to the Prediction of Longitudinal Functional Outcome in Schizophrenia
Overview
Authors
Affiliations
Objective: Functional impairment is characteristic of most individuals with schizophrenia; however, the key variables that undermine community functioning are not well understood. This study evaluated the association between selected clinical variables and one-year longitudinal functional outcomes in patients with schizophrenia.
Method: The sample included 754 patients with schizophrenia who completed both baseline and one-year follow-up visits in the CATIE study. Patients were evaluated with a comprehensive battery of assessments capturing symptom severity and cognitive performance among other variables. The primary outcome variable was functional status one-year postbaseline measured using the Heinrichs-Carpenter Quality of Life Scale.
Results: Factor analysis of negative symptom items revealed two factors reflecting diminished expression and amotivation. Multivariate regression modeling revealed several significant independent predictors of longitudinal functioning scores. The strongest predictors were baseline amotivation and neurocognition. Both amotivation and neurocognition also had independent predictive value for each of the domains of functioning assessed (e.g., vocational).
Conclusion: Both motivational and neurocognitive deficits independently contribute to longitudinal functional outcomes assessed 1 year later among patients with schizophrenia. Both of these domains of psychopathology impede functional recovery; hence, it follows that treatments ameliorating each of these symptoms should promote community functioning among individuals with schizophrenia.
Wang L, Li G, Yan C, Wang Y, Gao Y, Wang Y Schizophr Bull. 2025; 51(Supplement_2):S160-S172.
PMID: 40037829 PMC: 11879587. DOI: 10.1093/schbul/sbad116.
Delay C, Link P, Holden J, Granholm E Schizophr Res. 2025; 276:135-142.
PMID: 39889528 PMC: 11878216. DOI: 10.1016/j.schres.2025.01.014.
Social network reductions are associated with negative symptoms in schizophrenia.
Zhang L, James S, Standridge J, Condray R, Allen D, Strauss G Soc Psychiatry Psychiatr Epidemiol. 2024; .
PMID: 39658696 DOI: 10.1007/s00127-024-02804-0.
Cai H, Du R, Zhang J, Wang X, Li W, Yang K Front Pharmacol. 2024; 15:1478625.
PMID: 39564115 PMC: 11573587. DOI: 10.3389/fphar.2024.1478625.
Kammerer M, Nowak U, Lincoln T, Krkovic K Brain Sci. 2024; 14(5).
PMID: 38790425 PMC: 11119287. DOI: 10.3390/brainsci14050446.